Show simple item record

dc.contributor.authorWilliams, Jill M.
dc.contributor.authorZiedonis, Douglas M.
dc.contributor.authorFoulds, Jonathan
dc.date2022-08-11T08:10:26.000
dc.date.accessioned2022-08-23T17:08:46Z
dc.date.available2022-08-23T17:08:46Z
dc.date.issued2004-09-04
dc.date.submitted2010-08-28
dc.identifier.citationPsychiatr Serv. 2004 Sep;55(9):1064-6. <a href="http://dx.doi.org/10.1176/appi.ps.55.9.1064">Link to article on publisher's site</a>
dc.identifier.issn1075-2730 (Linking)
dc.identifier.doi10.1176/appi.ps.55.9.1064
dc.identifier.pmid15345771
dc.identifier.urihttp://hdl.handle.net/20.500.14038/45657
dc.description.abstractA retrospective case series of 12 smokers with schizophrenia or schizoaffective disorder who had not successfully quit smoking with previous treatments for tobacco dependence were treated with nicotine nasal spray. All but one patient (92 percent) tolerated the nasal spray well, and nine (75 percent) used it at maximal doses for prolonged periods. After treatment five patients (42 percent) were abstinent from smoking for more than 90 days, and four patients (33 percent) substantially reduced the amount that they smoked. Ten patients (83 percent) used the spray in combination with other medications, and all received psychosocial support. Nicotine nasal spray was found to be well tolerated.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=15345771&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1176/appi.ps.55.9.1064
dc.subjectAdministration, Intranasal
dc.subjectAdult
dc.subjectDrug Administration Schedule
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subject*Nebulizers and Vaporizers
dc.subjectNicotine
dc.subjectSmoking Cessation
dc.subject*Social Support
dc.subjectTobacco Use Disorder
dc.subjectPsychiatry
dc.titleA case series of nicotine nasal spray in the treatment of tobacco dependence among patients with schizophrenia
dc.typeJournal Article
dc.source.journaltitlePsychiatric services (Washington, D.C.)
dc.source.volume55
dc.source.issue9
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/psych_pp/192
dc.identifier.contextkey1482993
html.description.abstract<p>A retrospective case series of 12 smokers with schizophrenia or schizoaffective disorder who had not successfully quit smoking with previous treatments for tobacco dependence were treated with nicotine nasal spray. All but one patient (92 percent) tolerated the nasal spray well, and nine (75 percent) used it at maximal doses for prolonged periods. After treatment five patients (42 percent) were abstinent from smoking for more than 90 days, and four patients (33 percent) substantially reduced the amount that they smoked. Ten patients (83 percent) used the spray in combination with other medications, and all received psychosocial support. Nicotine nasal spray was found to be well tolerated.</p>
dc.identifier.submissionpathpsych_pp/192
dc.contributor.departmentDepartment of Psychiatry
dc.source.pages1064-6


This item appears in the following Collection(s)

Show simple item record